aldemyl 9.5 mg / 24 tuntia depotlaastari
mylan ab - rivastigminum - depotlaastari - 9.5 mg / 24 tuntia - rivastigmiini
emerpand 4.6 mg / 24 tuntia depotlaastari
actavis group ptc ehf - rivastigminum - depotlaastari - 4.6 mg / 24 tuntia - rivastigmiini
emerpand 9.5 mg / 24 tuntia depotlaastari
actavis group ptc ehf - rivastigminum - depotlaastari - 9.5 mg / 24 tuntia - rivastigmiini
emerpand 13.3 mg / 24 tuntia depotlaastari
actavis group ptc ehf - rivastigminum - depotlaastari - 13.3 mg / 24 tuntia - rivastigmiini
juliperla 75 mikrog / 20 mikrog tabletti
actavis group ptc ehf - gestodenum,ethinylestradiolum - tabletti - 75 mikrog / 20 mikrog - gestodeeni ja etinyyliestradioli
sofiperla 75 mikrog / 30 mikrog tabletti
actavis group ptc ehf - gestodenum,ethinylestradiolum - tabletti - 75 mikrog / 30 mikrog - gestodeeni ja etinyyliestradioli
rivastigmin ratiopharm 13.3 mg / 24 h depotlaastari
ratiopharm gmbh - rivastigminum - depotlaastari - 13.3 mg / 24 h - rivastigmiini
rivastor 13.3 mg / 24 tuntia depotlaastari
orion corporation - rivastigmine - depotlaastari - 13.3 mg / 24 tuntia - rivastigmiini
ontozry
angelini pharma s.p.a - cenobamate - epilepsia - epilepsialääkkeet, - adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products.
ztalmy
marinus pharmaceuticals emerald limited - ganaxolone - epileptic syndromes; spasms, infantile - muut epilepsialääkkeet - ztalmy is indicated for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (cdkl5) deficiency disorder (cdd) in patients 2 to 17 years of age. ztalmy may be continued in patients 18 years of age and older.